Prophylaxis for acute gout flares after initiation of urate-lowering therapy

Rheumatology (United Kingdom)

Volumn 53, Issue 11, 2014, Pages 1920-1926

  Latourte, Augustin ^a,b   Bardin, Thomas ^a   Richette, Pascal ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Anakinra; Canakinumab; Colchicine; Corticosteroids; Flares; Gout; Non steroidal anti inflammatory drug; Rilonacept; Urate lowering therapy

Indexed keywords

ALLOPURINOL; CANAKINUMAB; COLCHICINE; NAPROXEN; PREDNISOLONE; PREDNISONE; RILONACEPT; URATE; ANTIGOUT AGENT; URIC ACID;

ADVERSE DRUG REACTION; DISPERSION; DISSOLUTION; DRUG EFFICACY; GOUT; GOUT FLARE; HUMAN; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; PATHOGENESIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; ACUTE DISEASE; BLOOD; HYPERURICEMIA; METABOLISM;

ACUTE DISEASE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; URIC ACID;

EID: 84922320514     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu157     Document Type: Review

References (44)

1. Trifirò G, Morabito P, Cavagna L et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis 2013;72:694–700.
2. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312–24.
3. Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431–46.
4. Jordan KM, Cameron JS, Snaith M et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372–4.
5. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids 2008;27:585–91.
6. Schlesinger N, Mysler E, Lin H-Y et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011;70:1264–71.
7. Schumacher HR Jr, Sundy JS, Terkeltaub R et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012;64:876–84.
8. Mitha E, Schumacher HR, Fouche L et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology 2013;52:1285–92.
9. Borstad GC, Bryant LR, Abel MP et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429–32.
10. Joosten LAB, Netea MG, Mylona E et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010;62:3237–48.
11. Richette P, Bardin T. Purine-rich foods: an innocent bystander of gout attacks? Ann Rheum Dis 2012;71: 1435–6.
12. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E et al. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis 2009;68:273–8.
13. Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 2007;56:3183–8.
14. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237–41.
15. Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther 2010;12:206.
16. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008; 10:218–27.
17. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009;38:411–9.
18. Khanna D, Khanna PP, Fitzgerald JD et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447–61.
19. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355–9.
20. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28.
21. Schlesinger N, Alten RE, Bardin T et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, activecontrolled, double-blind trials and their initial extensions. Ann Rheum Dis 2012;71:1839–48.
22. Terkeltaub RA, Schumacher HR, Carter JD et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013;15:R25.
23. Schumacher HR Jr, Evans RR, Saag KG et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res 2012;64: 1462–70.
24. Dalbeth N, So A. Hyperuricaemia and gout: state of the art and future perspectives. Ann Rheum Dis 2010;69: 1738–43.
25. Sundy JS, Baraf HSB, Yood RA et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011;306:711–20.
26. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450–61.
27. Harrold LR, Andrade SE, Briesacher BA et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11:R46.
28. Bardin T, Richette P. New ACR guidelines for gout management hold some surprises. Nat Rev Rheumatol 2013;9: 9–11.
29. Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012;125:1126–34.
30. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013;72: 826–30.
31. Schumacher HR Jr, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540–8.
32. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63.
33. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-trea-ted patients. Arthritis Rheum 1974;17:609–14.
34. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010;32:2386–97.
35. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011;63:2226–37.
36. Keenan RT, O'Brien WR, Lee KH et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124:155–63.
37. Curiel RV, Guzman NJ. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. Semin Arthritis Rheum 2012;42:166–78.
38. Templeton JS. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report. Br J Clin Pract 1982;36:353–8.
39. Daymond TJ, Laws D, Templeton JS. A comparison of azapropazone and allopurinol in the treatment of chronic gout. Br J Clin Pharmacol 1983;15:157.
40. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098.
41. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology 2013;52:34–44.
42. Man CY, Cheung ITF, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670–7.
43. Janssens HJEM, Janssen M, van de Lisdonk EH, van Riel PLCM, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854–60.
44. Tran TH, Pham JT, Shafeeq H, Manigault KR, Arya V. Role of interleukin-1 inhibitors in the management of gout. Pharmacotherapy 2013;33:744–53.